A Study to Evaluate Safety and Clinical Activity of GSK5926371 in Adult Participants With Relapse… (NCT07607925) | Clinical Trial Compass
Not Yet RecruitingPhase 1/2
A Study to Evaluate Safety and Clinical Activity of GSK5926371 in Adult Participants With Relapsed or Refractory B-NHL
United States, Canada, Japan49 participantsStarted 2026-06-12
Plain-language summary
The goal of this clinical trial is to learn if drug GSK5926371 works to treat a form of B-cell cancer (a type of blood cancer) that has returned or failed to respond to prior therapies in adults. The study will primarily assess the drugs safety and tolerability in participants. Additionally, it seeks to determine the clinical efficacy and pharmacokinetic (PK) properties of GSK5926371.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Has measurable disease,
. Has received at least 2 prior lines of systemic anti-neoplastic therapy, including an anti-CD20-containing combination appropriate for the indication;
. Has documented disease relapse, progression or disease refractory to the most recent line of therapy, per Lugano criteria.:
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Since this is a Phase 1/2 trial and safety is one of the main things being studied, what do we actually know so far about how safe GSK5926371 is, and how does that uncertainty compare to my other treatment options right now?
2The trial is listed as 'not yet recruiting' — do you know when it's expected to open, and is it realistic to consider this given where my disease is right now and how quickly I may need to start treatment?
3Because this study is specifically measuring dose-limiting toxicities, meaning they're still figuring out how much of this drug is safe to give, what kinds of side effects are they watching for most closely, and how would my care be managed if I experienced a serious one?
4My lymphoma is described as relapsed or refractory B-NHL — based on my specific subtype and treatment history, do I look like someone who might fit what this trial is looking for, and are there standard salvage therapies I should consider first or instead?
5For a trial still in Phase 1/2 that hasn't started enrolling yet, what would the practical demands look like in terms of visits, monitoring, and travel, and how might that affect my day-to-day life while I'm already managing treatment?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Number of participants with dose limiting toxicities (DLTs)
Timeframe: Up to 28 days
2
Number of participants with adverse events (AEs) or Serious adverse events (SAEs) by severity